From the CC:
"... but what we expect from that project, as I mentioned in the earlier part of the conference call, is not only to expand that collaboration and further research, this big pharma company, the group we're working with, is actually, their microbial fermentation guide that are trying to internally convince their parent to get off of CHO. So they actually have the same goals and objectives as we do, so they're very excited about this and really committed to really push this forward. We actually started our initial call today with them, and was really exciting to hear that from them, that they're fully committed to making this work. But in addition to that, we're working with one of their affiliates, and that could become a major sort of relationship which speeds the adoption, provides more resources, speeds up the technology development, and broadens the adoption and use globally because that affiliate has a global outreach all over the globe. It's one of the largest providers of technology in the biotech industry. So we're affiliated with this pharma company as one of their company's affiliates. So it could be very exciting."
" we hope to get at least one if not more research license and potential commercial license or a research license with an option for commercial license from one or more of these agreements either with Sanofi or one of the ones we just signed. The one we signed this week, for example, so we have our fingers crossed it will be in 2020, it's possible it could be this year."
"
And I indicated earlier in the conference call when we sign one of these top 25 pharma company deals earlier this year, they've already now provided us with a second protein. So they're expanding seeing the results and they're expanding what they're doing with this and potentially that is going to go even further and faster. And as those results come in that potentially could turn into a license agreement as well. So there's a lot going on, a lot of different places. And of course Serum has already started and that could be just earth shattering in terms of the ability to really drive that cost down and do speedy adoption and use and force the industry to a new technology platform that can just change the game."
" The good thing with Serum is in addition to working with Serum, I can't get into it with you but it's not just Serum that's involved in these programs which probably can somebody that you can look online and there's certain people like the AIDS Foundation, funds research to Serum, WHL, the Gates Foundation, so as Serum succeeds and if we're successful in moving these products forward with them where we're getting more and more eyeballs with some of the big funding opportunities to provide us even more and more opportunities and just up to 12 proteins which are eight antibodies and four vaccines which are what we've talked about in the past. So it's much broader, much deeper there's a lot more eyeballs from the NIH from these big institutes and big funding organizations that are getting a peek. And we might have actually met with some of them in conjunction with that Serum deal and otherwise."
